Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer
Jinyuan Gu(Jiangsu Cancer Hospital), Wenbin Zhou(Nanjing Medical University), Kai Zhang(Nanjing Medical University), Hui Xie(Jiangsu Cancer Hospital), Xinyu Tang(University of California, Davis), Jiaming Wang(Bristol-Myers Squibb (Germany)), Yi Zhao(Jiangsu Province Hospital), Shui Wang(Jiangsu Provincial Academy of Environmental Science), Wang Ji(Zhejiang University), Yue Sun(City University of Hong Kong), Lijun Ling(Jiangsu Province Hospital), Cong Wang(Nanjing Medical University), Hong Pan(Nanjing Medical University), Xiaoan Liu(Nanjing Medical University), Xinrui Mao(Nanjing Medical University), Chao Qian(Nanjing Medical University)
Cited by 5
Related Papers
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
|Journal of Clinical Oncology|2018|976
Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis
|Allergy Asthma and Immunology Research|2018|383
A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
|International Journal of Biological Sciences|2016|286
The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy
|Journal of Hematology & Oncology|2019|276